Boehringer Ingelheim
CompanyGermanyFounded 1885
Boehringer Ingelheim develops 40 assets, the furthest approved, not sold in the US (Aggrenox). Mostly small molecule and antibody acting on PDE4B, PDE9A and SLC29A1; based in Germany, founded in 1885.
- 40
- Assets
- Furthest stage
- Approved, not sold in the US
- 830
- Trials
- 282
- Signals
Pipeline
40Fixed combination of aspirin and dipyridamole acting as antiplatelet agents
Approved, not sold in the US, Small molecule, SLC29A1, PDE4B, stroke (Phase 3), coronary artery disease (Phase 3)
Inhibits renal SGLT2, increasing urinary glucose excretion and lowering blood glucose.
Approved, Small molecule, SLC5A2, type 2 diabetes, heart failure
Inhibits HER2 signaling to suppress growth of HER2-driven cancer cells.
Approved, Small molecule, ERBB2, metastatic non squamous non small cell lung cancer
37 more assets
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
22 assets
1 asset
In the full profile
- Evidence behind the mechanisms12
- Trials1,003
- Deals1
- Signals20
- Integrity notices4
- Similar companies6
Papers
Annals of medicine, Nov 11, 2026
AHA Scientific Sessions 2026 abstract, Nov 9, 2026
AHA Scientific Sessions 2026 abstract, Nov 9, 2026
Survodutide met heart safety goal in adults with obesity
Lancet (London, England), Nov 9, 2026
Survodutide Improves Renal Function in Obesity-Related Kidney Injury in Uninephrectomized Mice
AHA Scientific Sessions 2026 abstract, Nov 7, 2026
Heart scan signs predicted greater benefit from empagliflozin
European journal of heart failure, Nov 5, 2026
ESC Congress 2026 abstract, Oct 26, 2026
iScience, Oct 19, 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England journal of medicine, Oct 2, 2026
ESC heart failure, Sep 22, 2026
Diabetes care, Sep 21, 2026
Deciphering senescence-associated mechanisms through cell painting & transcriptomics
npj aging, Sep 18, 2026
EANM Innovation, Sep 3, 2026
Diabetes therapy : research, treatment and education of diabetes and related disorders, Aug 14, 2026
Frontiers in bioscience (Landmark edition), Jul 30, 2026
Senescence targeting re-enables injury-responsive repair in a human RPE aging model
bioRxiv (Cold Spring Harbor Laboratory), Jun 30, 2026
Diabetes, Jun 5, 2026
Joint Variable Selection for Omic Biomarkers in Time-to-Event Data
bioRxiv (Cold Spring Harbor Laboratory), May 4, 2026
C94-10 Somatic Mosaicism of the X Chromosome Is Associated With Pulmonary Resilience in Women
American Journal of Respiratory and Critical Care Medicine, May 1, 2026
Frontiers in dementia, Apr 16, 2026